| 黄炳锋,陈伟.加减通窍活血汤联合倍他司汀对突发性耳聋(气滞血瘀证)患者听力阈值及血清Apo-B水平的影响[J].浙江中西医结合杂志,2025,35(10): |
| 加减通窍活血汤联合倍他司汀对突发性耳聋(气滞血瘀证)患者听力阈值及血清Apo-B水平的影响 |
| Impacts of modified Tongqiao Huoxue decoction combined with betamethasone on hearing threshold and serum Apo-B level in patients with sudden deafness (Qi stagnation and blood stasis syndrome) |
| 投稿时间：2024-12-23 修订日期：2025-04-15 |
| DOI： |
| 中文关键词: 加减通窍活血汤 倍他司汀 突发性耳聋 气滞血瘀证 听力阈值 血清载脂蛋白B |
| 英文关键词:Modified Tongqiao Huoxue decoction Betamethasone Sudden deafness Qi stagnation and blood stasis syndrome Hearing threshold Serum Apolipoprotein B |
| 基金项目:浙江省卫生健康科技计划项目(2021KY1099) |
|
| 摘要点击次数: 122 |
| 全文下载次数: 0 |
| 中文摘要: |
| 目的 探究加减通窍活血汤联合倍他司汀对突发性耳聋(SD)(气滞血瘀证)患者听力阈值及血清载脂蛋白B(Apo-B)水平的影响。方法 选择2021年6月~2024年3月本院收治的120例SD患者为研究对象,随机分为单一组及联合组各60例。单一组静滴盐酸倍他司汀,联合组在此基础上采用加减通窍活血汤对患者进行治疗。比较2组患者治疗前(T0)及治疗后(T1)的纯音测听(PTA)阈值、血液流变学指标水平、血清载脂蛋白(Apo)指标水平、血清炎症因子水平、中医证候评分及临床疗效。结果 T0时刻,2组PTA阈值、血液流变学指标水平、Apo指标水平、血清炎症因子水平及中医证候评分比较均无显著差异(P＞0.05)。T1时刻,2组PTA阈值、全血高、中、低切黏度、血浆黏度、红细胞比容、Apo-B水平、超敏C反应蛋白(hs-CRP)水平、肿瘤坏死因子-α(TNF-α)水平、耳聋伴耳胀闷感症状评分、耳鸣不休症状评分及舌质暗红症状评分均显著降低,Apo-AI及白介素-10(IL-10)水平明显升高,且联合组明显优于单一组(P＜0.05)。T1时刻,联合组SD的治疗总有效率显著高于单一组(P<0.05)。结论 加减通窍活血汤联合倍他司汀对SD(气滞血瘀证)患者的疗效显著,可有效抑制炎性因子的分泌,改善血液流变学水平,调节血清Apo代谢,从而降低患者PTA阈值,改善患耳听阈,有效缓解其临床症状,具有一定的临床应用价值。 |
| 英文摘要: |
| Objective To investigate the impacts of modified Tongqiao Huoxue decoction combined with betamethasone on hearing threshold and serum apolipoprotein B (Apo-B) level in patients with sudden deafness (SD) (qi stagnation and blood stasis syndrome). Methods A total of 120 SD patients admitted to our hospital from June 2021~March 2024 were selected as the study subjects and randomly separated into a single group and a combined group of 60 cases in each group. A single group received intravenous infusion of betamethasone hydrochloride, and on this basis, the patients were treated with modified Tongqi Huoxue decoction. The pure tone audiometry (PTA) threshold, hemorheological index level, serum apolipoprotein (Apo) index level, serum inflammatory factor level, TCM syndrome score and clinical efficacy were compared between the two groups before treatment (T0) and after treatment (T1). Results At T0, there were no significant differences in PTA threshold, hemorheological index level, Apo index level, serum inflammatory factor level and TCM syndrome score between the two groups (P>0.05). At T1, the PTA threshold, whole blood high, medium and low shear viscosity, plasma viscosity, hematocrit, Apo-B level, hypersensitive C-reactive protein (hs-CRP) level, tumor necrosis factor-α (TNF-α) level, deafness with ear swelling and stuffiness symptom score, tinnitus symptom score, and tongue dark red symptom score were greatly decreased in the two groups, and the levels of Apo-AI and interleukin-10 (IL-10) were greatly increased, and the combined group was greatly better than that of the single group (P<0.05). At T1, the total effective rate of SD in the combined group was greatly higher than that in the single group (P<0.05). Conclusion: The combination of modified Tongqiao Huoxue decoction and betamethasone has a great therapeutic effect on SD (Qi stagnation and blood stasis syndrome) patients. It can effectively inhibit the secretion of inflammatory factors, improve hemorheological levels, regulate serum Apo metabolism, thereby reducing PTA threshold, improving the affected ear hearing threshold, and effectively relieving their clinical symptoms. It has certain clinical application value. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
